VYNE Therapeutics (VYNE) Preferred Stock Liabilities (2016 - 2017)
VYNE Therapeutics (VYNE) posted Preferred Stock Liabilities of $44.8 million for Q4 2017, up 216.01% on a QoQ basis from $14.2 million in Q4 2016, and up 216.01% year-over-year from $14.2 million in Q4 2016.
VYNE Therapeutics (VYNE) Preferred Stock Liabilities (2016 - 2017) Analysis & Trends
VYNE Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $44.8 million for Q4 2017.
- Quarterly Preferred Stock Liabilities rose 216.01% year-over-year to $44.8 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $44.8 million (up 216.01% YoY) and the FY2017 annual result came in at $44.8 million, up 216.01% from the prior year.
- Preferred Stock Liabilities was $44.8 million for Q4 2017 at VYNE Therapeutics, up from $14.2 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $44.8 million in Q4 2017 and bottomed at $14.2 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 44.82 Mn |
| Dec 31, 2016 | 14.18 Mn |